JP2023510865A5 - - Google Patents

Info

Publication number
JP2023510865A5
JP2023510865A5 JP2022542777A JP2022542777A JP2023510865A5 JP 2023510865 A5 JP2023510865 A5 JP 2023510865A5 JP 2022542777 A JP2022542777 A JP 2022542777A JP 2022542777 A JP2022542777 A JP 2022542777A JP 2023510865 A5 JP2023510865 A5 JP 2023510865A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
approximately
angiolipoma
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022542777A
Other languages
English (en)
Japanese (ja)
Other versions
JP7850665B2 (ja
JP2023510865A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000035 external-priority patent/WO2021152390A1/en
Publication of JP2023510865A publication Critical patent/JP2023510865A/ja
Publication of JP2023510865A5 publication Critical patent/JP2023510865A5/ja
Application granted granted Critical
Publication of JP7850665B2 publication Critical patent/JP7850665B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542777A 2020-01-28 2021-01-27 血管脂肪腫の処置のための組成物 Active JP7850665B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062966577P 2020-01-28 2020-01-28
US62/966,577 2020-01-28
PCT/IB2021/000035 WO2021152390A1 (en) 2020-01-28 2021-01-27 Compositions for the treatment of angiolipoma

Publications (3)

Publication Number Publication Date
JP2023510865A JP2023510865A (ja) 2023-03-15
JP2023510865A5 true JP2023510865A5 (cg-RX-API-DMAC10.html) 2023-12-13
JP7850665B2 JP7850665B2 (ja) 2026-04-23

Family

ID=77078612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542777A Active JP7850665B2 (ja) 2020-01-28 2021-01-27 血管脂肪腫の処置のための組成物

Country Status (7)

Country Link
US (1) US20230089484A1 (cg-RX-API-DMAC10.html)
EP (1) EP4096653A4 (cg-RX-API-DMAC10.html)
JP (1) JP7850665B2 (cg-RX-API-DMAC10.html)
CN (1) CN115335047B (cg-RX-API-DMAC10.html)
AU (1) AU2021213469B2 (cg-RX-API-DMAC10.html)
IL (1) IL295014B1 (cg-RX-API-DMAC10.html)
WO (1) WO2021152390A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203468A1 (en) 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
EP4031130A4 (en) * 2019-09-15 2023-10-11 Raziel Therapeutics Ltd. COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS
US20240335424A1 (en) * 2021-07-28 2024-10-10 Raziel Therapeutics Ltd. Compositions and methods for treating lipoma pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058139A1 (en) * 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
WO2013072915A1 (en) * 2011-11-15 2013-05-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Tricyclic compounds, compositions comprising them and uses thereof
RU2020111934A (ru) * 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
AU2014340351B2 (en) * 2013-10-21 2020-01-30 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016020919A1 (en) * 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof
WO2016203468A1 (en) * 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof

Similar Documents

Publication Publication Date Title
JP2024543983A5 (cg-RX-API-DMAC10.html)
JP2025524914A5 (cg-RX-API-DMAC10.html)
JP2021534124A5 (cg-RX-API-DMAC10.html)
JP2022533069A5 (cg-RX-API-DMAC10.html)
JP2020533352A5 (cg-RX-API-DMAC10.html)
JP2021527125A5 (cg-RX-API-DMAC10.html)
JP2020507589A5 (cg-RX-API-DMAC10.html)
JP2021501754A5 (cg-RX-API-DMAC10.html)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
RU2020108488A (ru) Бета-гидрокси-гетероциклические амины и их применение для лечения гипергликемии
JP2021530513A5 (cg-RX-API-DMAC10.html)
JP2023535815A5 (cg-RX-API-DMAC10.html)
JP2006507326A5 (cg-RX-API-DMAC10.html)
JP2009530393A5 (cg-RX-API-DMAC10.html)
JP2021102643A5 (cg-RX-API-DMAC10.html)
JP2024545787A5 (cg-RX-API-DMAC10.html)
JP2019520344A5 (cg-RX-API-DMAC10.html)
JP2022509206A5 (cg-RX-API-DMAC10.html)
JP2023505434A5 (cg-RX-API-DMAC10.html)
JP2019529460A5 (cg-RX-API-DMAC10.html)
JP2022533939A5 (cg-RX-API-DMAC10.html)
JP2024507414A5 (cg-RX-API-DMAC10.html)
JP2023538524A5 (cg-RX-API-DMAC10.html)
JP2023503769A5 (cg-RX-API-DMAC10.html)
JP2024517769A5 (cg-RX-API-DMAC10.html)